Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study

References

• Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, et al. American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–8. doi:10.1182/bloodadvances.2019000966.
   PubMed Web of Science ®Google Scholar
• HAS. PNDS, Purpura thrombopénique immunologique de l’enfant et de l’adulte. Haute Aut Santé. 2017.
   Google Scholar
• Khellaf M, Charles-Nelson A, Fain O, Terriou L, Viallard J-F, Cheze S, Graveleau J, Slama B, Audia S, Ebbo M, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124(22):3228–36. doi:10.1182/blood-2014-06-582346.
   PubMed Web of Science ®Google Scholar
• Urquhart L. Top drugs and companies by sales in 2018. Nat Rev Drug Discov. 2019;18:245. doi:10.1038/d41573-019-00049-0.
   Web of Science ®Google Scholar
• Grampp G, Ramanan S. The diversity of biosimilar design and development: implications for policies and stakeholders. BioDrugs Clin Immunother Biopharm Gene Ther. 2015;29(6):365–72. doi:10.1007/s40259-015-0147-0.
   Google Scholar
• Food And Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product guidance for industry. 2015;27.
   Google Scholar
• World Heath Organization. WHO | Similar biotherapeutic products. WHO.
   Google Scholar
• Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues, EMA. 2012.
   Google Scholar
• Jurczak W, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, Castro N, Pereira J, Akria L, Alexeev S, et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017;4(8):e350–61. doi:10.1016/S2352-3026(17)30106-0.
   PubMed Web of Science ®Google Scholar
• Ogura M, Sancho JM, Cho S-G, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Lennard A, Mariz J, Ilyin N, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. Lancet Haematol. 2018;5(11):e543–53. doi:10.1016/S2352-3026(18)30157-1.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Cohen SB, Tony H-P, Scheinberg M, Kivitz A, Balanescu A, Gomez-Reino J, Cen L, Zhu P, Shisha T. A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2017;76(9):1598–602. doi:10.1136/annrheumdis-2017-211281.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Suh C-H, Shim SC, Jeka S, Cons-Molina FF, Hrycaj P, Wiland P, Lee EY, Medina-Rodriguez FG, Shesternya P, et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(3):566–70. doi:10.1136/annrheumdis-2016-209540.
   PubMed Web of Science ®Google Scholar
• État des lieux sur les médicaments biosimilaires, ANSM, Mai 2016. 2016.
   Google Scholar
• Deshayes S, Khellaf M, Zarour A, Layese R, Fain O, Terriou L, Viallard J-F, Cheze S, Graveleau J, Slama B, et al. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITP-ritux. Am J Hematol. 2019;94(12):1314–24. doi:10.1002/ajh.25632.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–93. doi:10.1182/blood-2008-07-162503.
   PubMed Web of Science ®Google Scholar
• Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica. 2005;90:829–32.
   PubMed Web of Science ®Google Scholar
• Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, Vekhoff A, Chauveheid M-P, Stirnemann J, Galicier L, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999–1004. doi:10.1182/blood-2008-01-131029.
   PubMed Web of Science ®Google Scholar
• Marangon M, Vianelli N, Palandri F, Mazzucconi MG, Santoro C, Barcellini W, Fattizzo B, Volpetti S, Lucchini E, Polverelli N, et al. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. Eur J Haematol. 2017;98(4):371–7. doi:10.1111/ejh.12839.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Lee CS, Seery C, Imahiyerobo AA, Thompson MV, Catellier D, Turenne IG, Patel VL, Basciano PA, Elstrom RL, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica. 2014;99(7):1264–71. doi:10.3324/haematol.2013.103291.
   PubMed Web of Science ®Google Scholar
• Healthcare expenditure statistics.
   Google Scholar
• Mageau A, Terriou L, Ebbo M, Souchaud‐debouverie O, Orvain C, Graveleau J, Lega J-C, Ruivard M, Viallard J-F, Cheze S, et al. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: new insights for an old treatment. Am J Hematol. 2022;97(1):10–17. doi:10.1002/ajh.26378.
   PubMed Web of Science ®Google Scholar
• Mahévas M, Ebbo M, Audia S, Bonnotte B, Schleinitz N, Durand J-M, Chiche L, Khellaf M, Bierling P, Roudot‐thoraval F, et al. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia. Am J Hematol. 2013;88(10):858–61. doi:10.1002/ajh.23518.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood. 2005;106(3):795–802. doi:10.1182/blood-2004-08-3198.
   PubMed Web of Science ®Google Scholar
• Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medi (Baltimore). 2010;89(5):308–18. doi:10.1097/MD.0b013e3181f2caef.
   PubMed Web of Science ®Google Scholar
• Malpica Castillo LE, Palmer S, Zhu A, Deal AM, Chen S-L, Moll S. Incidence and time course of neutropenia in patients treated with rituximab-based therapy for non-malignant immune-mediated hematologic diseases. Am J Hematol. 2020;95(5):E117–20. doi:10.1002/ajh.25751.
   PubMed Web of Science ®Google Scholar
• Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125(2):232–9. doi:10.1111/j.1365-2141.2004.04889.x.
   PubMed Web of Science ®Google Scholar